Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Autoinducer-1 (AI-1) quorum sensing pathway is a primary communication system used by Gram-negative bacteria to coordinate collective behaviors based on population density (Miller & Bassler, 2001). It typically consists of a LuxI-type synthase that produces signaling molecules known as N-acyl homoserine lactones (AHLs) and a cognate LuxR-type receptor that acts as a signal-dependent transcription factor (Papenfort & Bassler, 2016). When the concentration of AHLs reaches a critical threshold, they bind to the LuxR receptor, triggering the expression of genes involved in virulence, biofilm formation, and antibiotic resistance (Rutherford & Bassler, 2012). Targeting this pathway, a strategy known as quorum quenching, aims to disarm pathogens without killing them, potentially reducing the selective pressure for antibiotic resistance (Defoirdt, 2018). This approach is particularly relevant for treating chronic infections caused by pathogens like Pseudomonas aeruginosa, where AI-1 signaling regulates the production of destructive enzymes and toxins (Whiteley et al., 2017). Small molecule inhibitors and enzymes that degrade AHLs are currently being explored as therapeutic agents to enhance the efficacy of traditional antibiotics (Dong et al., 2001). However, challenges remain regarding the specificity of these agents and their potential impact on the host's commensal microbiome (Zhang & Li, 2016).
Competitive antagonism of LuxR-type receptors, inhibition of LuxI-type AHL synthases, and enzymatic degradation of AHL signaling molecules (quorum quenching).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Autoinducer-1 quorum sensing pathway (AI-1 QS).